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1. Introduction 
Dementia is a debilitating condition frequent in ageing populations, and Alzheimer’s Disease 
(AD) accounts for 70% of all dementia cases. AD is characterized by neuropathological 
hallmarks consisting of an accumulation of Amyloid ß peptide (Aß) in extracellular plaques, 
intracellular deposits of tau protein, neuronal loss and, more recently, a prominent synaptic 
loss was identified (Braak and Braak, 1991; Masliah et al., 2001; Selkoe, 1991; Spires-Jones 
and Hyman, 2014). In addition, anatomical studies in AD patients showed a massive loss of 
brain white matter and a specific reduction of cholinergic neurons of the basal forebrain (Auld 
et al., 2002; Bowen et al., 1976; Coyle et al., 1983; Kim et al., 2013; Whitehouse et al., 1981, 
1982). Cholinergic neurons are organized in dense nuclei with widespread projections that 
entirely cover the central nervous system. In particular, the cholinergic neurons, whose cell 
bodies are in the basal forebrain, send their long projections to the neocortex and 
hippocampus (Bigl et al., 1982; Mesulam et al., 1983). Several studies demonstrated the 
pivotal role of these cholinergic nuclei in cognitive functions. Woolf (1998) proposed a model 
in which acetylcholine (ACh) release leads to the modulation of cortical circuitry that finally 
encodes for storage of long-term memory. The cholinergic system is also involved in attention 
processes (Muir et al., 1993; Sarter and Bruno, 1997; Wenk, 1997). In a mouse model, the 
lack of ACh receptors in the prefrontal cortex (PFC) was demonstrated to be responsible for 
attention deficit, restored by the expression of the receptor in this area (Guillem et al., 2011). 
The neurotransmitter ACh binds to two families of receptors, nicotinic acetylcholine receptors 
(nAChRs) and muscarinic acetylcholine receptors (mAChRs). Both families of receptors 
regulate the cognitive processes mentioned above (Ghoneim and Mewaldt, 1977; Petersen, 
1977; Sarter and Paolone, 2011), and are both affected in AD. 
Binding studies performed with the use of [3H]-nicotine and [3H]-ACh showed a significant 
reduction in nicotine and ACh binding sites in cerebral cortex of patients suffering from AD, 
demonstrating a decrease of both nAChR and mAChR populations (Gotti et al., 2006a; 
Paterson and Nordberg, 2000; Perry et al., 1981, 1985, 1987, 1988; Shimohama et al., 1986; 
Whitehouse et al., 1981, 1982, 1986). In addition to nAChRs and mAChRs, the enzyme 
choline acetyltransferase (ChAT), involved in ACh production, is also affected in AD. The 
activity of this ChAT enzyme, and consequently the synthesis of ACh, is decreased in AD 
brains. In addition, several authors observed a reduction in the activity of acetylcholinesterase 
(AChE), the enzyme that metabolises ACh after its release in the synaptic cleft (Auld et al., 
2002; Bowen et al., 1976; Coyle et al., 1983; Davies and Maloney, 1976; Perry et al., 1978). 
The role of the cholinergic system in cognition and the modification observed in 
neurodegenerative diseases, and in particular in the case of AD, led to the formulation of the 
“cholinergic hypothesis” of geriatric disorders (Bartus et al., 1982; Contestabile, 2011), 
according to which the reduction in cholinergic innervation is responsible for the cognitive 
decline observed in AD patients. 
In this context, we will focus on nAChRs, since their involvement in AD has been largely 
demonstrated, while the contribution of mAChRs has been under-explored. The purpose of 
this review is to present evidence implicating the role of nAChRs in AD, discuss the data 
supporting their interaction with Aß, and the consequences of the perturbation of this 
interaction in murine models. 
 
2. Brief overview of nAChR subtypes involved in AD  
Nicotinic receptors are transmembrane pentameric proteins that belong to the “cys-loop”	  
superfamily of ligand-gated ion channels together with GABAA, GABAC, glycine and 5-
hydroxytryptamine (5-HT3) ionotropic receptors (Changeux and Edelstein, 1998; Le Novère 
and Changeux, 1995). They are composed of a variety of α	  and β	  subunits, which determine 
the pharmacological and kinetic properties of the receptor (Albuquerque et al., 2009; 
Giniatullin et al., 2005). The five subunits that compose the receptor are assembled around a 
central hydrophilic pore that mediates the flow of the cations K+, Na+ and Ca++. In the human 
nervous system, there are eight α	  subunits (α2-α7, α9, α10) and three ß	  subunits (ß2-ß4) that 
assemble in different combinations to generate a variety of nAChR subtypes with distinct 
electrophysiological properties and brain localization (Albuquerque et al., 2009; Gotti et al., 
2006b, 2007, 2009). 
The use of radioactive ligands allowed nAChR classification into two distinct groups, 
αBungarotoxin sensitive and αBungarotoxin insensitive receptors (Gotti and Clementi, 2004). 
Homopentameric α7 nAChRs belong to the first class, while heteropentameric nAChRs 
containing the ß2 subunit belong to the second class. In this context we will focus on these α7 
and ß2 subunits, that were shown to interact with Aß (Liu et al., 2009, 2012; Søderman et al., 
2008; Sudweeks and Yakel, 2000; Wang et al., 2000a, 2000b). 
The α7 homomeric receptor demonstrates a wide-spread localization in the brain and is 
characterized by a high calcium ion permeability and a fast desensitization rate (Dani and 
Bertrand, 2007; Quick and Lester, 2002). α7 nAChR on presynaptic terminals mediate release 
of others neurotransmitters (Wonnacott et al., 2006), while a postsynaptic or somatic 
localization elicits important changes in intracellular Ca++ concentration, that can activate 
second messenger pathways mediating cellular processes such as neuronal survival and gene 
expression (Berg and Conroy, 2002; Messi et al., 1997; Morley and Happe, 2000). Moreover, 
it was demonstrated that the activation of α7 nAChRs is important during development for the 
maturation of glutamatergic synapses (Lozada et al., 2012). 
The role of α7 in memory and attention has been investigated for a long time. Knock-out 
(KO) mice for this subunit did not show a clear cognitive or attention deficit, except when the 
behavioural paradigm used implied prolonged sessions (Young et al., 2004, 2007). 
Historically, the first nAChR subunit identified to interact with Aß was α7 (Wang et al., 
2000a, 2000b). Later it was shown that Aß is able to activate also ß2*-nAChRs (ß2 subunit-
containing nAChRs). This subunit commonly forms heteropentameric receptors in 
combination with the α4 subunit. The pharmacological and functional characteristics of these 
heteromeric receptors are determined by both the contributing α	  and ß	  subunits. The subtype 
α4ß2 is characterized by lower calcium ion permeability and a slow desensitization rate 
compared to the homopentameric α7 nAChR (Quick and Lester, 2002). The “classic” high-
affinity nAChR is composed of α4 and ß2 subunits (Zoli et al., 1998). In addition to the α4ß2 
subtype, it was demonstrated that the α7 subunit is able to co-assemble with the ß2 subunit to 
form a heteropentameric receptor. This novel α7ß2 subtype was first investigated by 
expressing the heteromer in Xenopus oocytes. Recently, the α7ß2* nAChR subtype was found 
in basal forebrain cholinergic neurons and hippocampal interneurons of mouse brain, and in 
the human basal forebrain (Moretti et al., 2014). This class of receptors seems to be 
particularly sensitive to Aß-induced toxicity (Khiroug et al., 2002; Liu et al., 2009, 2012). The 
existence of this novel subtype was further confirmed in a human cell line (SHEP-1) 
transfected with the cDNA for α7 and ß2 subunits. Under these experimental conditions, α7 
and ß2 are able to co-assemble into a functional receptor that localizes at the cell surface. The 
ability of α7 and ß2 subunits to form a functional receptor was confirmed in X. laevis oocytes. 
This heteromer displayed only a modest difference in the electrophysiological response to 
pharmacological agents compared to the homomeric α7 nAChR (Murray et al., 2012). The 
exact stoichiometry of this recently discovered subtype was not defined. It is clear that 
functional ligand binding domains could only be formed at the α7-α7 interface. Murray et al. 
(2012) proposed a schematic model of all the possible stoichiometries for the α7ß2 subtype. 
The importance of ß2 in maintaining brain homeostasis during normal ageing was highlighted 
in the KO mouse for this subunit. Aged ß2 null mutant mice have a thinner cortex compared 
to age-matched wild-type controls (Zoli et al., 1999). This work should be pursued further as 
it indicates a “neurotrophic” action of ß2 receptor activation by endogenous ACh (Zanardi et 
al., 2007). Null mutant ß2 mice were also tested to determine the role of this subunit in 
cognition. Guillem et al. (2011) showed that these mice exhibit an attention deficit which was 
restored by re-expression of this subunit with a lentiviral vector in the PFC. 
We will now present and discuss the data demonstrating the existence of a physical 
interaction between nAChR and Aß, the functional consequences of this interaction and the 
intracellular pathways activated. 
 
3. Interaction between nAChRs and Aß 
The interaction between the α7 nAChR and Aß is widely demonstrated. The first indication of 
this interaction came from the experiments of Wang et al. (2000a, 2000b). They showed that 
α7 subunits co-localize with Aß1-42 in senile plaques of brain slices obtained from patients that 
suffered from sporadic AD. In this context, no co-localization was found between Aß	  and the 
α4 subunit. The strong and specific association between Aß	  and α7, and no other subunits of 
the nAChRs, was further demonstrated with immunoprecipitation and Western Blot analysis. 
This set of experiments showed that Aß1-42 is able to immunoprecipitate α7, which was not the 
case for other nAChR subunits such as α1, α3, α4, α8 or ß2. The same result was obtained 
with the reciprocal experiment, α7 immunoprecipitation and Aß1-42 detection, meaning that 
the two proteins strongly interact. Experiments performed with fragments of Aß helped 
identify the sequence responsible for the interaction with α7, which corresponds to the amino 
acid residues 12-28 of the Aß	   sequence (Wang et al., 2000b). Subsequently, competition 
studies performed by incubating α7 nAChRs with Aß	   and αBungarotoxin showed that the 
application of αBungarotoxin is able to decrease the amount of Aß	   bound to α7 nAChRs, 
suggesting that both molecules compete for the same ligand binding domain (Wang et al., 
2000b). Furthermore, studies using two selective nicotinic receptor ligands, namely 
[3H]methyllycaconitine and [3H]cytisine, clearly showed that α7 nAChRs bind the less toxic 
peptide Aß1-40, but with lower affinity compared to the 1-42 form (Wang et al., 2000a). Direct 
interaction between Aß	   and α7 was further demonstrated in a transgenic mouse line, 
APPSwe/PS1ΔE9, where α7 was shown to immunoprecipitate with Aß1-40/42 (Søderman et al., 
2008). Modulation of nAChRs by Aß was also found in ex vivo studies: Pettit and colleagues 
(2001) used rat hippocampal slices to show that Aß1-42 incubation is able to reduce 
postsynaptic currents and open probability of both α7 and non-α7 nAChRs subtypes, 
demonstrating an interaction between Aß	   and other nAChR subunits. Even though studies 
have mainly focused on the interaction between α7 nAChRs and Aß	   and its functional 
consequences, it has been demonstrated that also ß2*-nAChRs bind to Aß. The evidence 
supporting this interaction comes mostly from electrophysiological studies (Lamb et al., 2005; 
Liu et al., 2009, 2012; Wu et al., 2004). 
Several papers from the Yakel laboratory (Lamb et al., 2005; Pandya and Yakel, 2011; Pettit 
et al., 2001) have investigated the action of Aß on these heteromeric receptors. In both 
hippocampal interneurons and oocytes they observed a block of ß2*-nAChRs, that could be 
prevented by the application of a positive allosteric modulator (PAM) specific for ß2 subunit 
containing receptors, desformylflustrabromine (dFBr) (Pandya and Yakel, 2011). These are 
the only conclusive studies to our knowledge, and it will probably be important to continue 
this dissection. 
 
4. Functional consequences of nAChR-Aß	  interaction 
In this paragraph we will summarize the extensive literature that covers nAChR functional 
activation or inhibition mediated by Aß, with emphasis on nAChR subtype, Aß concentration 
and experimental model used. The literature presents conflicting results about functional 
consequences of Aß binding on nAChRs, eliciting in some studies a receptor activation, and 
in others an inhibition (Pettit et al., 2001; Puzzo et al., 2008; Tozaki et al., 2002). In order to 
be able to compare and interpret these contrasting observations, we should be aware of the 
variability stemming from the different approaches used, such as the difference in receptor 
subtype (homo- or hetero-pentameric receptors), the system used for electrophysiological 
recordings (Xenopus oocytes that express transiently the subunits versus organotypic slices 
and cellular systems), and most importantly, the Aß	   preparation used (concentration and 
aggregation status). For instance, there is variability in the characteristics and toxicity of the 
oligomeric vs fibrillar species of Aß (Selkoe, 2011; Walsh and Selkoe, 2004). Below, we will 
summarize the most remarkable findings over the past years.	  
Important evidence for a functional interaction between nAChRs and Aß	  came from the work 
of Pettit et al (2001). They demonstrated that Aß1-42 drives a reversible inhibition of nAChR-
mediated currents in hippocampal GABAergic neurons recorded from rat slices. In these 
experimental conditions the most effective Aß1-42 concentration was 500nM, but inhibition 
was found also at the lower concentration of 100nM. With the use of selective antagonists it 
was possible to determine that inhibition operates on both α7 and non-α7 receptors (Pettit et 
al., 2001). Experiments performed on Xenopus laevis oocytes transiently transfected with α7 
or α4ß2 cDNA showed a concentration dependent effect of Aß	  on receptor inhibition. In this 
case the peptide used was Aß1-40 and the concentrations adopted were between 0.1 and 10 µM, 
with increased Aß	  concentration resulting in a bigger inhibition of the receptor (Tozaki et al., 
2002). A different set of experiments demonstrated that Aß enhances ACh activation of the 
α4ß2 nAChRs expressed in oocytes, this first activation of the receptor was followed by its 
inhibition (Pym et al., 2005). However, α7 nAChR activation was observed in X. laevis 
oocytes when a range of Aß concentration spanning from 1 to 100 pM was applied (Dineley 
et al., 2002). Using a different experimental model, Liu et al. (2001) obtained a different 
outcome. The incubation of cultured rat hippocampal neurons with Aß1-42 resulted in 
inhibition of α7 nAChRs, more precisely of both somato-dendritic and presynaptic 
populations of receptors. In this case, non-α7 nAChRs were insensitive to Aß	  inhibition (Liu 
et al., 2001). Further studies showed an inhibitory effect of Aß1-42 on human α4ß2 nAChRs 
trasnfected in the cell line (SHEP1) (Wu et al., 2004). Other work performed in cellular 
systems on human nAChRs showed receptor activation. The oligomeric form of Aß1-40 was 
able to activate α7 nAChR expressed in SH-SY5Y cell line (Lilja et al., 2011). Arora et al. 
(2013) investigated, in a cellular system, the effect of prolonged Aß exposure on nAChR 
function. The rodent neuroblastoma cell line NG108-15 was transfected with α4ß2 nAChRs 
and treated for three days with 100 nM Aß. The following acute stimulation with Aß and 
nicotine led to receptor activation that caused a perturbation of intracellular calcium 
homeostasis followed by mitochondrial dysfunction and increased oxidative stress (Arora et 
al., 2013). In a different study, rat hippocampus and cortex were investigated and the 
activation of both α7 and non-α7 receptors was obtained with an enhancement of Ca++ influx 
into the neuron following the application of picomolar (pM) concentrations of Aß1-42. In this 
case, a distinct response of homomeric and heteromeric receptors was found, specifically, α7 
are activated at pM concentrations of Aß, while non-α7 receptors were responsive at nM Aß	  
concentrations (Dougherty et al., 2003). A study performed on nerve endings with application 
of Aß	  demonstrated a non competitive action of Aß1-40 on α4ß2 nAChR (Olivero et al., 2014). 
In conclusion, the outcome of receptor activation or inhibition depends on the system used 
and on Aß	   concentration. In general, it is possible to summarize that short incubation and 
lower concentration lead to receptor activation (Dineley et al., 2002; Dougherty et al., 2003; 
Puzzo et al., 2008), while longer incubation period and higher peptide concentrations give rise 
to an inhibitory effect (Dineley et al., 2001; Parri et al., 2011; Pettit et al., 2001). However, 
due to the variability in the experimental models used, the concentration and aggregation form 
of Aß (see Table 1), and in the obtained data, it is not possible to definitively conclude 
whether Aß	  binding on nAChRs exerts an inhibitory or excitatory effect in a physiological 
context. 
However, it is clear that nAChR-Aß	  interaction initiates intracellular signalling implicating a 
set of transduction cascades. Akt phosphorylation mediates the downstream activation of an 
anti-apoptotic pathway, which is also activated by nicotine treatment (Kihara et al., 2001). 
The molecular pathways activated are associated with neuroprotection, synaptic plasticity, 
learning and memory (Plant et al., 2003; Puzzo et al., 2008). Subsequent to incubation with 
pM concentrations of Aß1-42 monomers and oligomers, an increase of hippocampal LTP was 
observed. This enhancement of synaptic plasticity and the activation of intracellular pathways 
are mediated by the activation of α7 nAChRs (Dineley et al., 2001; Parri et al., 2011; Plant et 
al., 2003; Puzzo et al., 2008). An in vivo Aß	   infusion in mice was able to enhance 
hippocampal dependent memory, highlighted with memory tasks such as the Morris water 
maze and contextual fear conditioning, which are both hippocampus dependent behavioural 
tasks (Puzzo et al., 2008). On the other hand, an opposite effect was shown with Aß-nAChR 
interaction being responsible for inhibition of survival pathways. In this system enhancement 
of Akt phosphorylation and activation of ERK pathway was observed following α7 agonist 
treatment, suggesting that Aß inhibits the neuroprotective effect of α7 nAChR activation (Zhi 
et al., 2014). Even though some key differences in Aß	  concentration used among the different 
studies are present, it is possible to conclude that in certain conditions Aß	  activates survival 
pathways. It was then postulated that Aß-nAChR interaction has a physiological role in 
neuronal homeostasis that is disrupted when Aß	   concentrations increase in a pathological 
context, leading to receptor inhibition and possible cellular toxicity (Dineley et al., 2001; Parri 
et al., 2011). 
 
5. nAChR null-mutants in AD 
An interesting approach to study the role of nAChRs in AD in vivo is to generate KO 
transgenic mice for nAChRs subunits expressing fAD (familial AD) associated mutations. 
This method was used to investigate the role of the α7 subunit in AD, a strategy that has so far 
not been used for the other nAChR subunits. Two examples from the literature showed 
strikingly opposite outcomes (Dziewczapolski et al., 2009; Hernandez et al., 2010). In the first 
study conducted by Dziewczapolski et al. (2009), a mouse model, that we will refer to as 
APP-α7KO, was generated by crossing an AD model that expresses the human APP 
(Amyloid precursor protein) with the Swedish (KM670/671NL) and the Indiana (V717F) 
mutations (Mucke et al., 2000), with the α7 nAChR null-mutant (Orr-Urtreger et al., 1997). 
This AD model displays spatial memory deficit at 13-16 months of age, while APP-α7KO 
mice did not exhibit any memory deficit, suggesting that the absence of the α7 subunit of the 
nicotinic receptor protects against	  the behavioural deficit caused by expression of the mutated 
forms of APP in this AD model. It is known that AD mice display some pathological 
modifications, like loss of synaptic and dendritic markers, such as synaptophysin and MAP2 
(Games et al., 1995; Hsia et al., 1999). In the APP-α7KO line the lack of α7 was sufficient to 
preserve synaptic terminals and dendrites, rescuing levels of synaptophysin and MAP2 to 
reach that of aged-matched WT controls. To investigate whether the difference in APP 
expression in the different mouse lines was responsible of the lack of neuropathology, 
Western Blot and ELISA analyses were performed. These experiments confirmed that the 
level of expression of APP and the consequent synthesis of Aß	  were comparable between 
mouse lines, demonstrating that the difference in cognitive deficit and neuropathology were 
mediated exclusively by the nicotinic receptor. In addition, APP mice demonstrated a deficit 
in LTP while APP-α7KO mice did not display this phenotype. The authors postulated that the 
absence of α7 could prevent Aß	   intracellular accumulation ameliorating the cognitive 
neuropathology and its phenotypic association (Dziewczapolski et al., 2009).	  
A second study was published by Hernandez et al. (2010). In their work, the transgenic AD 
model line Tg2576 expressing the human APP sequence with the Swedish mutation (Hsiao et 
al., 1996) was crossed with the α7 KO mouse (Orr-Urtreger et al., 1997) to establish a 
different APP-α7KO line. In this series of experiments the mice were tested with a panel of 
behavioural tasks at five months of age, investigating the role of α7 in early AD. The 
contextual fear conditioning and the novel object recognition tasks both showed that the 
cognitive deficits worsen when α7 is absent. In the hippocampus, it was shown that APP-
α7KO mice had high levels of Aß, although significantly less than APP mice, an effect which 
is not due to modification of the APP expression level, equivalent in the two lines. As a 
consequence of the lower Aß	   concentration, the plaque load was clearly reduced in APP-
α7KO mice. Signs of neuropathology were found in APP-α7KO illustrated by loss of MAP2 
immunoreactivity in the hippocampus. In conclusion, this study demonstrated the protective 
role of α7 nAChRs. The mechanism proposed is that the Aß-α7 nAChR interaction could 
activate neuroprotective downstream pathways (Parri et al., 2011), and that at the same time 
the interaction engages Aß	  preventing its aggregation. With the progression of the disease the 
amount of Aß	   increases, it starts to accumulate, and becomes toxic for the neurons 
(Hernandez et al., 2010).	  
In conclusion, α7 nAChRs seem to have a dual effect depending on the age of the mice tested 
and probably on Aß	   concentration and aggregation state. However, the AD model used to 
generate the APP-α7KO line express different fAD associated mutations (Swedish and 
Indiana mutations in Dziewczapolski et al., 2009; Swedish mutation in Hernandez et al., 
2010). The different mutations cause AD pathology to develop in distinct ways, making it 
difficult to directly compare the results (see Table 2).	  
 
6. Pharmacological interference between α7 nAChR-Aß	  binding 
A possible therapeutic approach for AD treatment is the use of nAChR agonists or antagonists 
to interfere with nAChR-Aß	   interaction. Numerous molecules with agonist or antagonist 
activity on nAChRs exist. The protective role of these molecules against Aß toxicity was 
widely demonstrated using many experimental models and approaches. Gao et al. (2014) 
investigated the neuroprotective effect of cotinine, nicotine and their analogs, in vitro on 
primary cultures of rat cortical and hippocampal neurons. Cotinine is a nicotine metabolite 
known for its positive effects on memory and attention and lower toxicity compared to 
nicotine (Hatsukami et al., 1997). Methyllycaconitine (MLA), an α7 nAChR antagonist, 
showed neuroprotective effect on mouse and rat primary cell culture (Martin et al., 2004). 
Another molecule investigated was 2-[2-(4- bromophenyl)-2-oxoethyl]-1-methyl pyridinium 
(S 24795), a partial α7 nAChR agonist. When this molecule was applied to synaptosomal 
preparations from rat frontal cortex and post mortem human AD samples it was able to 
dissociate Aß	  in a concentration dependent manner. The incubation with S 24795 was able to 
normalize Ca++ influx mediated by both	  α7 nAChR and NMDAR (Wang et al., 2009, 2010). 
Many other examples of neuroprotective effects elicited by nAChR agonists exist in the 
literature. However, here we will focus on the results obtained with in vivo experimentation. 
The first attempt to treat an AD mouse model with nicotine was performed by Nordberg et al. 
(2002). The transgenic line harbouring Swedish double mutations (Hsiao et al., 1996) was 
treated for 5.5 months with nicotine in the drinking water. APPSwe mice showed a reduction in 
plaque load of 80% compared to sucrose treated mice. The analysis of the Aß	  fraction reduced 
by nicotine showed that mainly insoluble Aß1-40/42 was affected while there was no change in 
soluble Aß (Nordberg et al., 2002). Another study investigated the effect of short and long-
term nicotine treatment in the same APPSwe line. Nicotine was administered through 
subcutaneous injections for 10 consecutive days on 9 month old transgenic mice. For long-
term administration, mice were treated with nicotine in the drinking water for a period of 5.5 
months. The short-term treatment of 10 days showed a significant reduction in cortical 
insoluble Aß1-40/42. Long-term nicotine administration elicited a reduction in Aß deposits in 
blood vessel. APPSwe mice at 14.5 months have fewer αBungarotoxin binding sites, while in 
transgenic mice treated with nicotine the number of αBungarotoxin binding sites was 
recovered and comparable to non transgenic age-matched control mice, suggesting that there 
was an increase in the population of α7 nAChRs (Hellström-Lindahl et al., 2004). Inestrosa et 
al. (2013) then investigated the effect of intraperitoneal nicotine injections in the APP/PS1 
double transgenic line. This line expresses fAD associated mutations in both APP and 
Presenilin 1 proteins. Mice aged 6 months were treated for one month with nicotine 
injections, which led to an improvment in working and episodic memory compared to non- 
treated transgenic mice. This study investigated the effect of nicotine delivery on both young 
and old mice. For this purpose, 12 month old mice were treated with nicotine injections, and 
then tested for spatial memory. Like the young mice, they also displayed an improvement in 
spatial memory, demonstrating that nicotine enhances memory in both young and old mice. 
The amount of Aß	   was quantified, and following nicotine injections a reduction in Aß, 
particularly in the oligomeric form, was found. This work confirmed the observation that AD 
mouse models display a reduction of α7 binding sites and PSD-95 puncta reflecting a synaptic 
deficit in this line. Both α7 binding sites and PSD-95 puncta were increased following 
nicotine treatment. The explanation proposed by the authors is that α7 nAChR activation 
through nicotine binding could promote survival pathways and recover the synaptic damage 
caused by Aß (Inestrosa et al., 2013). Oddo et al. (2005) investigated the consequences of 
nAChR activation on tau pathology in AD model 3xTg-AD. This line was chosen because it 
showed cholinergic pathology with a decrease of α7 nAChRs in brain regions affected by Aß 
deposition and tau aggregation. Chronic nicotine administration was performed in drinking 
water for 5 months. The long-term nicotine treatment caused faster tau aggregation in CA1 
pyramidal neurons. The possible mechanism by which nicotine enhances the aggregation of 
tau is through the activation of p38-MAP kinase. This kinase is sensitive to Ca++, whose 
levels are increased following nAChR activation (Oddo et al., 2005). Even though nicotine 
showed a positive effect reducing plaque load (Hellström-Lindahl et al., 2004; Inestrosa et al., 
2013; Nordberg et al., 2002), its use in AD treatment should be limited due to its toxic effect 
on tau pathology. 
Shim et al. (2008) investigated the effect of nicotine administration in an AD mouse model 
harbouring the Swedish mutation. 12 month old mice were treated with three different doses 
of nicotine (5 mg/kg, 30 mg/kg and 180 mg/kg) in drinking water for 6 months. Nicotine 
treatment improved the memory deficit, highlighted with the Morris water maze task. 
Surprisingly, this study showed a dose dependent increase of α7 nAChR, a result that is in 
contrast with the literature (Oddo et al., 2005). In the group that received the higher dose of 
nicotine, the level of α7 nAChR was restored to the level found in wild-type animals (Shim et 
al., 2008). However, nicotine is addictive and has numerous side effects, for example on the 
cardiovascular system. The use of cotinine for the treatment of AD was also investigated. We 
already cited an in vitro study on the protective effect of cotinine against Aß toxicity (Gao et 
al., 2014). In a mouse model of AD, cotinine treatment decreased the plaque load and was 
able to activate the Akt pathway, that was shown to be neuroprotective (Echeverria et al., 
2011). Cotinine is an α7 nAChR PAM (positive allosteric modulator). It was already 
demonstrated that this molecule does not display side effects when administrated in humans 
(Hatsukami et al., 1997). Thus, cotinine is an interesting molecule for AD treatment (for a 
review see Echeverria and Zeitlin, 2012). 
The neuroprotective effect of 4OH-GTS-21, an α7 nAChR agonist, was also investigated. The 
molecule was administered to PS1 and APP/PS1trangenic mice following a lesion to the 
fimbria fornix region (FFX). This novel model displayed deficits in spatial memory and 
reduced neuronal density. Whilst the spatial memory deficit was restored by 4OH-GTS-21 
treatment, this molecule had no effect on neuronal density (Ren et al., 2007). Wild-type mice 
treated with nicotine or with SSR180711, another partial agonist of α7 (Biton et al., 2006), 
showed increased LTP, while the transgenic AD model APPSwe/PS1ΔE9 showed no effect 
on LTP following SSR180711 treatment. The authors performed an autoradiographic study to 
investigate the number of α7 nAChR binding sites. Surprisingly, no decrease was found when 
transgenic and wild-type mice were compared, a result in contrast with work from other 
authors (Shim et al., 2008). The molecule SSR180711 seems to be effective in enhancing LTP 
in wild-type mice but is not able to interfere with Aß-nAChR binding, thus not being 
considered for AD treatment (Söderman et al., 2011). 
Pregnenolone sulfate (PREGS) is an endogenous steroid known to ameliorate cognitive 
performance in animals. PREGS is a modulator of synaptic plasticity, acting on the activation 
of glutamatergic transmission (Smith et al., 2014). It was proposed that the positive action of 
PREGS is mediated by α7 nAChR. In order to investigate this hypothesis, Yang et al. (2012) 
treated a mouse model obtained with injection of Aß25-35 for 7 days whit PREGS. The 
treatment improved spatial memory and reduced apoptosis in CA1 pyramidal cells. Even 
though the protective effect of PREGS is evident, less clear is whether or not it implies α7 
nAChR activation (Yang et al., 2012). 
Simvastatin (SV) is a statin commonly used in the clinic to control cholesterol levels and it 
was shown to improve cognitive function in AD patients (Simons et al., 2002; Sparks et al., 
2006). In a study conducted by Zhi et al. (2014), this molecule was used to treat a mouse 
model obtained with injections of the peptide Aß25-35. Administration for 11 days of SV 
improved memory performance in the Morris water maze task and promoted survival of CA1 
pyramidal cells. This effect was proposed to be promoted by α7 nAChRs, since it is blocked 
by MLA administration (Zhi et al., 2014).	  
A caveat with these pharmacological studies directed at α7 nAChRs is the contribution of 
potential off-target effects, hence other approaches have been investigated. The intracellular 
signaling initiated by the binding of Aß	  to nAChR at the cell surface requires the recruitment 
of Filamin A (FLNA), a scaffold protein that is known to crosslink actin, and in addition 
could also have a function in certain intracellular pathways (Stossel et al., 2001). Wang et al. 
showed that the association between FLNA and the α7 subunit is elevated in AD samples 
compared to age matched controls. A novel molecule called PTI-125 was used to interfere 
with the interaction of FLNA and α7. The treatment with PTI-125 prevents FLNA binding to 
α7 and as consequence reduces the affinity of Aß	  for nAChRs, attenuating the toxic effect of 
Aß	  (Wang et al., 2012).	  
 
7. Conclusion 
In this review we present evidence supporting the existence of a direct interaction between 
nAChRs and Aß. The effect of Aß on nAChR physiology is complex. It was indeed shown 
that this interaction can lead to either activation of survival pathways or to a toxic effect. 
Under different experimental conditions, Aß can act like an agonist or an antagonist on 
AChRs, which underlies the observed variability. Thus, nAChR activation, for example with 
nicotine, can have a protective effect against Aß exerted toxicity, with the clearance of the 
peptide. However, this interaction should be studied further to understand the cellular 
mechanism(s) underlying the activation of survival pathways and Aß clearance, observed 
following nicotine administration. Moreover, the use of different α7 agonists to target this 
nAChR subtype is a promising approach that can be translated into AD therapy. Despite the 
fact that mainly the α7 subunit was investigated in the AD field, some data demonstrating the 
functional interaction between Aß and non-α nAChRs also exist. We believe that other 
nAChR subunits could be a target of Aß toxicity and their contribution to AD pathology 
should be elucidated. 
Agonist molecules are responsible for the activation of the receptor at the surface of the cell, 
and scaffold proteins anchoring nicotinic receptors mediate and regulate the transduction of 
the intracellular signal. These proteins that interact with the receptors, or directly linked 
interacting proteins, are largely unknown. In addition to nAChRs, these proteins also present 
future targets for the study of neurodegeneration research and potential treatment. 
Finally, the possibility to generate multiple transgenic models expressing fAD associated 
mutations and KOs for nAChR subunits was explored. This approach showed apparently 
contrasting results that however could reflect a different role (protective or not) of the 
nicotinic receptors depending on Aβ concentration.  
Significant evidence suggesting a potential role of nAChRs as therapeutic target in AD exists. 
These studies provide support for pursuing the investigations to define the detailed 
mechanism of nAChR neuroprotection and design nAChR agonists, antagonists or allosteric 
modulators for clinical translation. 
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Table Legends 
Table 1 
Action of Aß on nAChRs: The incubation with Aß activates or inhibits nAChRs. Here we 
summarised the results from the literature with particular attention on the Aß fragment and 
concentrations used, the model in which the experiments were performed and the nAChR 
subtype investigated. 
 
Table 2 
Conflicting data on α7 KO crossed with AD model: Comparison of two published studies 
showing the AD model used for the generation of the APP- α7KO line, the phenotype of the 
obtained APP- α7KO with the age of tested mice and the overall effect of α7 nAChRs. 
